Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants
At very high doses, furosemide is linked to ototoxicity in adults, but little is known about the risk of hearing loss in premature infants exposed to furosemide. Evaluate the association between prolonged furosemide exposure and abnormal hearing screening in premature infants. Using propensity scori...
Gespeichert in:
| Veröffentlicht in: | Early human development 2018-10, Vol.125, p.26-30 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 30 |
|---|---|
| container_issue | |
| container_start_page | 26 |
| container_title | Early human development |
| container_volume | 125 |
| creator | Wang, Laura A. Smith, P. Brian Laughon, Matthew Goldberg, Ronald N. Ku, Lawrence C. Zimmerman, Kanecia O. Balevic, Stephen Clark, Reese H. Benjamin, Daniel K. Greenberg, Rachel G. |
| description | At very high doses, furosemide is linked to ototoxicity in adults, but little is known about the risk of hearing loss in premature infants exposed to furosemide.
Evaluate the association between prolonged furosemide exposure and abnormal hearing screening in premature infants.
Using propensity scoring, infants with prolonged (≥28 days) exposure to furosemide were matched to infants never exposed. The matched sample was used to estimate the impact of prolonged furosemide exposure on the probability of an abnormal hearing screen prior to hospital discharge.
A cohort of infants 501–1250 g birth weight and 23–29 weeks gestational age discharged home from 210 neonatal intensive care units in the United States (2004–2013).
We defined abnormal hearing screen as a result of either “fail” or “refer” for either ear.
Altogether, 1020 infants exposed to furosemide for ≥28 days were matched to 790 unique infants never exposed, yielding a total of 1042 matches due to sampling with replacement and propensity score ties. Matching resulted in a population similar in baseline characteristics. After adjusting for covariates, the proportion of infants with an abnormal hearing screen in the furosemide-exposed group was not significantly higher than the never-exposed group (absolute difference 3.0% [95% CI −0.2–6.2%], P = 0.07).
Prolonged furosemide exposure was associated with a positive, but not statistically significant, difference in abnormal hearing screening in premature infants. Additional studies with post-hospital discharge audiology follow-up are needed to further evaluate the safety of furosemide in this population.
•Prolonged furosemide was not associated with a significant difference in abnormal hearing screening in premature infants.•The findings from our study have important implications for understanding the safety of furosemide in premature infants.•Additional studies with extended follow-up are needed to further evaluate the safety of furosemide in this population. |
| doi_str_mv | 10.1016/j.earlhumdev.2018.08.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6186186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378378218304286</els_id><sourcerecordid>2101272408</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-4ec00dc1626ff4dd3d974555d3b472e85de19884ccc9f1a84d847992469d1fee3</originalsourceid><addsrcrecordid>eNqFUU2PFCEUJEbjzq7-BcPRS48Pmu6Gi4lu_Eo20YNeJQw8Zhi7YYTuWf33Mpl11ZNJEQ6vqt5LFSGUwZoB61_s12jyuFsmh8c1BybXUAHqAVkxOfCm5y1_SFbQDrKpj1-Qy1L2ANBJBY_JRQtMtYx3K_L1U05jilt01C85FZyCQ4o_DqksGamJjuZQvtHkqdnElCcz0oi3m5Qj3dUjQtzSYjNipCHSQ8bJzCdhiN7EuTwhj7wZCz69-6_Il7dvPl-_b24-vvtw_eqmsWJQcyPQAjjLet57L5xrnRpE13Wu3YiBo-wcMiWlsNYqz4wUTlad4qJXjnnE9oq8PPsels2EzmKcsxn1IYfJ5J86maD_ncSw09t01D2TJ1SD53cGOX1fsMx6CsXiOJqIaSma19z5wAXISpVnqq15lYz-fg0DfapH7_WfevSpHg0VoKr02d9n3gt_91EJr88ErGEdA2ZdbMBo0YWMdtYuhf9v-QU99qm9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2101272408</pqid></control><display><type>article</type><title>Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Wang, Laura A. ; Smith, P. Brian ; Laughon, Matthew ; Goldberg, Ronald N. ; Ku, Lawrence C. ; Zimmerman, Kanecia O. ; Balevic, Stephen ; Clark, Reese H. ; Benjamin, Daniel K. ; Greenberg, Rachel G.</creator><creatorcontrib>Wang, Laura A. ; Smith, P. Brian ; Laughon, Matthew ; Goldberg, Ronald N. ; Ku, Lawrence C. ; Zimmerman, Kanecia O. ; Balevic, Stephen ; Clark, Reese H. ; Benjamin, Daniel K. ; Greenberg, Rachel G. ; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee</creatorcontrib><description>At very high doses, furosemide is linked to ototoxicity in adults, but little is known about the risk of hearing loss in premature infants exposed to furosemide.
Evaluate the association between prolonged furosemide exposure and abnormal hearing screening in premature infants.
Using propensity scoring, infants with prolonged (≥28 days) exposure to furosemide were matched to infants never exposed. The matched sample was used to estimate the impact of prolonged furosemide exposure on the probability of an abnormal hearing screen prior to hospital discharge.
A cohort of infants 501–1250 g birth weight and 23–29 weeks gestational age discharged home from 210 neonatal intensive care units in the United States (2004–2013).
We defined abnormal hearing screen as a result of either “fail” or “refer” for either ear.
Altogether, 1020 infants exposed to furosemide for ≥28 days were matched to 790 unique infants never exposed, yielding a total of 1042 matches due to sampling with replacement and propensity score ties. Matching resulted in a population similar in baseline characteristics. After adjusting for covariates, the proportion of infants with an abnormal hearing screen in the furosemide-exposed group was not significantly higher than the never-exposed group (absolute difference 3.0% [95% CI −0.2–6.2%], P = 0.07).
Prolonged furosemide exposure was associated with a positive, but not statistically significant, difference in abnormal hearing screening in premature infants. Additional studies with post-hospital discharge audiology follow-up are needed to further evaluate the safety of furosemide in this population.
•Prolonged furosemide was not associated with a significant difference in abnormal hearing screening in premature infants.•The findings from our study have important implications for understanding the safety of furosemide in premature infants.•Additional studies with extended follow-up are needed to further evaluate the safety of furosemide in this population.</description><identifier>ISSN: 0378-3782</identifier><identifier>ISSN: 1872-6232</identifier><identifier>EISSN: 1872-6232</identifier><identifier>DOI: 10.1016/j.earlhumdev.2018.08.009</identifier><identifier>PMID: 30193125</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Bronchopulmonary Dysplasia - drug therapy ; Diuretic ; Diuretics - adverse effects ; Diuretics - therapeutic use ; Evoked Potentials, Auditory, Brain Stem - physiology ; Female ; Furosemide - adverse effects ; Furosemide - therapeutic use ; Gestational Age ; Hearing loss ; Hearing Loss - chemically induced ; Hearing Loss - diagnosis ; Hearing Tests ; Humans ; Infant, Newborn ; Infant, Premature ; Intensive Care Units, Neonatal ; Male ; Ototoxicity ; Pregnancy ; Preterm ; Safety</subject><ispartof>Early human development, 2018-10, Vol.125, p.26-30</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-4ec00dc1626ff4dd3d974555d3b472e85de19884ccc9f1a84d847992469d1fee3</citedby><cites>FETCH-LOGICAL-c479t-4ec00dc1626ff4dd3d974555d3b472e85de19884ccc9f1a84d847992469d1fee3</cites><orcidid>0000-0003-4156-8543</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.earlhumdev.2018.08.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30193125$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Laura A.</creatorcontrib><creatorcontrib>Smith, P. Brian</creatorcontrib><creatorcontrib>Laughon, Matthew</creatorcontrib><creatorcontrib>Goldberg, Ronald N.</creatorcontrib><creatorcontrib>Ku, Lawrence C.</creatorcontrib><creatorcontrib>Zimmerman, Kanecia O.</creatorcontrib><creatorcontrib>Balevic, Stephen</creatorcontrib><creatorcontrib>Clark, Reese H.</creatorcontrib><creatorcontrib>Benjamin, Daniel K.</creatorcontrib><creatorcontrib>Greenberg, Rachel G.</creatorcontrib><creatorcontrib>Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee</creatorcontrib><title>Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants</title><title>Early human development</title><addtitle>Early Hum Dev</addtitle><description>At very high doses, furosemide is linked to ototoxicity in adults, but little is known about the risk of hearing loss in premature infants exposed to furosemide.
Evaluate the association between prolonged furosemide exposure and abnormal hearing screening in premature infants.
Using propensity scoring, infants with prolonged (≥28 days) exposure to furosemide were matched to infants never exposed. The matched sample was used to estimate the impact of prolonged furosemide exposure on the probability of an abnormal hearing screen prior to hospital discharge.
A cohort of infants 501–1250 g birth weight and 23–29 weeks gestational age discharged home from 210 neonatal intensive care units in the United States (2004–2013).
We defined abnormal hearing screen as a result of either “fail” or “refer” for either ear.
Altogether, 1020 infants exposed to furosemide for ≥28 days were matched to 790 unique infants never exposed, yielding a total of 1042 matches due to sampling with replacement and propensity score ties. Matching resulted in a population similar in baseline characteristics. After adjusting for covariates, the proportion of infants with an abnormal hearing screen in the furosemide-exposed group was not significantly higher than the never-exposed group (absolute difference 3.0% [95% CI −0.2–6.2%], P = 0.07).
Prolonged furosemide exposure was associated with a positive, but not statistically significant, difference in abnormal hearing screening in premature infants. Additional studies with post-hospital discharge audiology follow-up are needed to further evaluate the safety of furosemide in this population.
•Prolonged furosemide was not associated with a significant difference in abnormal hearing screening in premature infants.•The findings from our study have important implications for understanding the safety of furosemide in premature infants.•Additional studies with extended follow-up are needed to further evaluate the safety of furosemide in this population.</description><subject>Bronchopulmonary Dysplasia - drug therapy</subject><subject>Diuretic</subject><subject>Diuretics - adverse effects</subject><subject>Diuretics - therapeutic use</subject><subject>Evoked Potentials, Auditory, Brain Stem - physiology</subject><subject>Female</subject><subject>Furosemide - adverse effects</subject><subject>Furosemide - therapeutic use</subject><subject>Gestational Age</subject><subject>Hearing loss</subject><subject>Hearing Loss - chemically induced</subject><subject>Hearing Loss - diagnosis</subject><subject>Hearing Tests</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Infant, Premature</subject><subject>Intensive Care Units, Neonatal</subject><subject>Male</subject><subject>Ototoxicity</subject><subject>Pregnancy</subject><subject>Preterm</subject><subject>Safety</subject><issn>0378-3782</issn><issn>1872-6232</issn><issn>1872-6232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUU2PFCEUJEbjzq7-BcPRS48Pmu6Gi4lu_Eo20YNeJQw8Zhi7YYTuWf33Mpl11ZNJEQ6vqt5LFSGUwZoB61_s12jyuFsmh8c1BybXUAHqAVkxOfCm5y1_SFbQDrKpj1-Qy1L2ANBJBY_JRQtMtYx3K_L1U05jilt01C85FZyCQ4o_DqksGamJjuZQvtHkqdnElCcz0oi3m5Qj3dUjQtzSYjNipCHSQ8bJzCdhiN7EuTwhj7wZCz69-6_Il7dvPl-_b24-vvtw_eqmsWJQcyPQAjjLet57L5xrnRpE13Wu3YiBo-wcMiWlsNYqz4wUTlad4qJXjnnE9oq8PPsels2EzmKcsxn1IYfJ5J86maD_ncSw09t01D2TJ1SD53cGOX1fsMx6CsXiOJqIaSma19z5wAXISpVnqq15lYz-fg0DfapH7_WfevSpHg0VoKr02d9n3gt_91EJr88ErGEdA2ZdbMBo0YWMdtYuhf9v-QU99qm9</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Wang, Laura A.</creator><creator>Smith, P. Brian</creator><creator>Laughon, Matthew</creator><creator>Goldberg, Ronald N.</creator><creator>Ku, Lawrence C.</creator><creator>Zimmerman, Kanecia O.</creator><creator>Balevic, Stephen</creator><creator>Clark, Reese H.</creator><creator>Benjamin, Daniel K.</creator><creator>Greenberg, Rachel G.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4156-8543</orcidid></search><sort><creationdate>20181001</creationdate><title>Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants</title><author>Wang, Laura A. ; Smith, P. Brian ; Laughon, Matthew ; Goldberg, Ronald N. ; Ku, Lawrence C. ; Zimmerman, Kanecia O. ; Balevic, Stephen ; Clark, Reese H. ; Benjamin, Daniel K. ; Greenberg, Rachel G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-4ec00dc1626ff4dd3d974555d3b472e85de19884ccc9f1a84d847992469d1fee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Bronchopulmonary Dysplasia - drug therapy</topic><topic>Diuretic</topic><topic>Diuretics - adverse effects</topic><topic>Diuretics - therapeutic use</topic><topic>Evoked Potentials, Auditory, Brain Stem - physiology</topic><topic>Female</topic><topic>Furosemide - adverse effects</topic><topic>Furosemide - therapeutic use</topic><topic>Gestational Age</topic><topic>Hearing loss</topic><topic>Hearing Loss - chemically induced</topic><topic>Hearing Loss - diagnosis</topic><topic>Hearing Tests</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Infant, Premature</topic><topic>Intensive Care Units, Neonatal</topic><topic>Male</topic><topic>Ototoxicity</topic><topic>Pregnancy</topic><topic>Preterm</topic><topic>Safety</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Laura A.</creatorcontrib><creatorcontrib>Smith, P. Brian</creatorcontrib><creatorcontrib>Laughon, Matthew</creatorcontrib><creatorcontrib>Goldberg, Ronald N.</creatorcontrib><creatorcontrib>Ku, Lawrence C.</creatorcontrib><creatorcontrib>Zimmerman, Kanecia O.</creatorcontrib><creatorcontrib>Balevic, Stephen</creatorcontrib><creatorcontrib>Clark, Reese H.</creatorcontrib><creatorcontrib>Benjamin, Daniel K.</creatorcontrib><creatorcontrib>Greenberg, Rachel G.</creatorcontrib><creatorcontrib>Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Early human development</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Laura A.</au><au>Smith, P. Brian</au><au>Laughon, Matthew</au><au>Goldberg, Ronald N.</au><au>Ku, Lawrence C.</au><au>Zimmerman, Kanecia O.</au><au>Balevic, Stephen</au><au>Clark, Reese H.</au><au>Benjamin, Daniel K.</au><au>Greenberg, Rachel G.</au><aucorp>Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants</atitle><jtitle>Early human development</jtitle><addtitle>Early Hum Dev</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>125</volume><spage>26</spage><epage>30</epage><pages>26-30</pages><issn>0378-3782</issn><issn>1872-6232</issn><eissn>1872-6232</eissn><abstract>At very high doses, furosemide is linked to ototoxicity in adults, but little is known about the risk of hearing loss in premature infants exposed to furosemide.
Evaluate the association between prolonged furosemide exposure and abnormal hearing screening in premature infants.
Using propensity scoring, infants with prolonged (≥28 days) exposure to furosemide were matched to infants never exposed. The matched sample was used to estimate the impact of prolonged furosemide exposure on the probability of an abnormal hearing screen prior to hospital discharge.
A cohort of infants 501–1250 g birth weight and 23–29 weeks gestational age discharged home from 210 neonatal intensive care units in the United States (2004–2013).
We defined abnormal hearing screen as a result of either “fail” or “refer” for either ear.
Altogether, 1020 infants exposed to furosemide for ≥28 days were matched to 790 unique infants never exposed, yielding a total of 1042 matches due to sampling with replacement and propensity score ties. Matching resulted in a population similar in baseline characteristics. After adjusting for covariates, the proportion of infants with an abnormal hearing screen in the furosemide-exposed group was not significantly higher than the never-exposed group (absolute difference 3.0% [95% CI −0.2–6.2%], P = 0.07).
Prolonged furosemide exposure was associated with a positive, but not statistically significant, difference in abnormal hearing screening in premature infants. Additional studies with post-hospital discharge audiology follow-up are needed to further evaluate the safety of furosemide in this population.
•Prolonged furosemide was not associated with a significant difference in abnormal hearing screening in premature infants.•The findings from our study have important implications for understanding the safety of furosemide in premature infants.•Additional studies with extended follow-up are needed to further evaluate the safety of furosemide in this population.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>30193125</pmid><doi>10.1016/j.earlhumdev.2018.08.009</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-4156-8543</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-3782 |
| ispartof | Early human development, 2018-10, Vol.125, p.26-30 |
| issn | 0378-3782 1872-6232 1872-6232 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6186186 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Bronchopulmonary Dysplasia - drug therapy Diuretic Diuretics - adverse effects Diuretics - therapeutic use Evoked Potentials, Auditory, Brain Stem - physiology Female Furosemide - adverse effects Furosemide - therapeutic use Gestational Age Hearing loss Hearing Loss - chemically induced Hearing Loss - diagnosis Hearing Tests Humans Infant, Newborn Infant, Premature Intensive Care Units, Neonatal Male Ototoxicity Pregnancy Preterm Safety |
| title | Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A57%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolonged%20furosemide%20exposure%20and%20risk%20of%20abnormal%20newborn%20hearing%20screen%20in%20premature%20infants&rft.jtitle=Early%20human%20development&rft.au=Wang,%20Laura%20A.&rft.aucorp=Best%20Pharmaceuticals%20for%20Children%20Act%20%E2%80%93%20Pediatric%20Trials%20Network%20Steering%20Committee&rft.date=2018-10-01&rft.volume=125&rft.spage=26&rft.epage=30&rft.pages=26-30&rft.issn=0378-3782&rft.eissn=1872-6232&rft_id=info:doi/10.1016/j.earlhumdev.2018.08.009&rft_dat=%3Cproquest_pubme%3E2101272408%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2101272408&rft_id=info:pmid/30193125&rft_els_id=S0378378218304286&rfr_iscdi=true |